Invasive Bloodstream Infections in Children: The Antifungal Susceptibility, Clinical Characteristics and Impacts on Outcomes

Overview

Journal Microorganisms

Specialty Microbiology

Date 2023 Jun 15

PMID 37317123

Authors

Yao-Sheng Wang

Jen-Fu Hsu

Wei-Ju Lee

Shao-Hung Wang

Shih-Ming Chu

Hsuan-Rong Huang

Peng-Hong Yang

Ren-Huei Fu

Ming-Horng Tsai

Affiliations

Soon will be listed here.

Abstract

: is the most common non- candida species that causes invasive candidiasis, but little is known about its impacts on the outcomes of pediatric patients. We aimed to characterize the clinical characteristics, risk factors and outcomes of bloodstream infections (BSIs) in children. : All pediatric patients with BSIs between 2005 and 2020 from a medical center in Taiwan were enrolled and analyzed. The antifungal susceptibility, clinical manifestations, management and outcomes were investigated. Cases of BSIs were compared between patients with BSIs and other Candida spp. BSIs. : During the study period, 95 episodes (26.0% of total cases) of BSIs were identified and analyzed. No significant difference was found between pediatric patients with BSIs and those with BSIs in terms of patients' demographics, most chronic comorbidities or risk factors. Pediatric patients with BSIs were significantly more likely to have previous azole exposure and be on total parenteral nutrition than those with BSIs (17.9 vs. 7.6% and 76.8 vs. 63.7%, = 0.015 and 0.029, respectively). The duration of candidemia was relatively longer, and therefore patients often required a longer duration of antifungal treatment when compared with those of candidemia, although the candidemia-attributable mortality rates were comparable. Of the isolates, 93.7% were susceptible to all antifungal agents, and delayed appropriate antifungal treatment was an independent factor in treatment failure. : Pediatric patients with BSIs were more likely to have previous azole exposure and be on total parenteral nutrition, and the clinical significances included a longer duration of candidemia and patients often required a longer duration of antifungal treatment.

References

Almirante B, Rodriguez D, Cuenca-Estrella M, Almela M, Sanchez F, Ayats J . Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2006; 44(5):1681-5. PMC: 1479182. DOI: 10.1128/JCM.44.5.1681-1685.2006. View

Stefanek M, Wenner S, Borges V, Pinto M, Gomes J, Rodrigues J . Antimicrobial Resistance and Biofilms Underlying Catheter-Related Bloodstream Coinfection by Complex and . Antibiotics (Basel). 2022; 11(9). PMC: 9495738. DOI: 10.3390/antibiotics11091245. View

Yamin D, Husin A, Harun A . Risk Factors of Catheter-Related Bloodstream Infection. Front Public Health. 2021; 9:631865. PMC: 8387826. DOI: 10.3389/fpubh.2021.631865. View

Siopi M, Tarpatzi A, Kalogeropoulou E, Damianidou S, Vasilakopoulou A, Vourli S . Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature. Antimicrob Agents Chemother. 2019; 64(3). PMC: 7038287. DOI: 10.1128/AAC.01516-19. View

Donnelly J, Chen S, Kauffman C, Steinbach W, Baddley J, Verweij P . Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019; 71(6):1367-1376. PMC: 7486838. DOI: 10.1093/cid/ciz1008. View

Garzillo C, Bagattini M, Bogdanovic L, Di Popolo A, Iula V, Catania M . Risk factors for Candida parapsilosis bloodstream infection in a neonatal intensive care unit: a case-control study. Ital J Pediatr. 2017; 43(1):10. PMC: 5347820. DOI: 10.1186/s13052-017-0332-5. View

Tsai M, Chu S, Lee C, Hsu J, Huang H, Chiang M . Recurrent late-onset sepsis in the neonatal intensive care unit: incidence, clinical characteristics and risk factors. Clin Microbiol Infect. 2014; 20(11):O928-35. DOI: 10.1111/1469-0691.12661. View

Tsai M, Chu S, Hsu J, Lien R, Huang H, Chiang M . Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU. Pediatrics. 2014; 133(2):e322-9. DOI: 10.1542/peds.2013-1248. View

Fernandez-Ruiz M, Guinea J, Lora-Pablos D, Zaragoza O, Puig-Asensio M, Almirante B . Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance. Clin Microbiol Infect. 2017; 23(9):672.e1-672.e11. DOI: 10.1016/j.cmi.2017.01.014. View

10.

Papadimitriou-Olivgeris M, Spiliopoulou A, Fligou F, Spiliopoulou I, Tanaseskou L, Karpetas G . Risk factors and predictors of mortality of candidaemia among critically ill patients: role of antifungal prophylaxis in its development and in selection of non-albicans species. Infection. 2017; 45(5):651-657. DOI: 10.1007/s15010-017-1050-z. View

11.

Yamin D, Husin A, Harun A . Distribution of candidemia in Malaysian tertiary care hospital revealed predominance of Candida parapsilosis. Trop Biomed. 2021; 37(4):903-910. DOI: 10.47665/tb.37.4.903. View

12.

Montravers P, Perrigault P, Timsit J, Mira J, Lortholary O, Leroy O . Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units. Clin Microbiol Infect. 2016; 23(2):117.e1-117.e8. DOI: 10.1016/j.cmi.2016.10.001. View

13.

Arendrup M, Meletiadis J, Mouton J, Guinea J, Cuenca-Estrella M, Lagrou K . EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin Microbiol Infect. 2016; 22(6):571.e1-4. DOI: 10.1016/j.cmi.2016.01.017. View

14.

Chen C, Sheng W, Huang S, Chou W, Yao M, Tang J . Clinical characteristics and treatment outcomes of patients with candidaemia due to Candida parapsilosis sensu lato species at a medical centre in Taiwan, 2000-12. J Antimicrob Chemother. 2015; 70(5):1531-8. DOI: 10.1093/jac/dku540. View

15.

Phua A, Hon K, Holt A, OCallaghan M, Bihari S . Candida catheter-related bloodstream infection in patients on home parenteral nutrition - Rates, risk factors, outcomes, and management. Clin Nutr ESPEN. 2019; 31:1-9. DOI: 10.1016/j.clnesp.2019.03.007. View

16.

Branco J, Miranda I, Rodrigues A . Virulence and Antifungal Resistance Mechanisms: A Comprehensive Review of Key Determinants. J Fungi (Basel). 2023; 9(1). PMC: 9862255. DOI: 10.3390/jof9010080. View

17.

Dogan O, Yesilkaya A, Menekse S, Guler O, Karakoc C, Cinar G . Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group. Int J Antimicrob Agents. 2020; 56(1):105992. DOI: 10.1016/j.ijantimicag.2020.105992. View

18.

Lai M, Hsu J, Chu S, Wu I, Huang H, Lin C . Breakthrough candidemia in children: clinical and microbiological characteristics, therapeutic strategies and impact on outcomes. Future Microbiol. 2017; 12:695-705. DOI: 10.2217/fmb-2016-0223. View

19.

Lee W, Hsu J, Chen Y, Wang S, Chu S, Huang H . Pediatric Bloodstream Infections Complicated with Mixed and Subsequent Bacteremia: The Clinical Characteristics and Impacts on Outcomes. J Fungi (Basel). 2022; 8(11). PMC: 9695890. DOI: 10.3390/jof8111155. View

20.

Ngamchokwathana C, Chongtrakool P, Waesamaae A, Chayakulkeeree M . Risk Factors and Outcomes of Non- Bloodstream Infection in Patients with Candidemia at Siriraj Hospital-Thailand's Largest National Tertiary Referral Hospital. J Fungi (Basel). 2021; 7(4). PMC: 8066724. DOI: 10.3390/jof7040269. View